VC-backed CytomX Therapeutics files for IPO
South San Francisco-based CytomX Therapeutics, a biopharmaceutical company focused on treating cancer, has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be determined. The company plans on trading the stock on the NASDAQ under the ticker symbol "CTMX." BofA Merrill Lynch, Jefferies LLC and Cowen and Company LLC will serve as the lead underwriters. CytomX's backers include Fidelity Management & Research Company, Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners and Wellington Management Company.
31 August 2015•2 mins read
